Camilla Borglin

Camilla Borglin is an accomplished Director of Product Development for Formulation & Drug Delivery at Ferring Pharmaceuticals, leading a skilled team responsible for formulation development across various modalities, including small molecules, peptides, proteins, gene therapy, and living organisms since November 2012. Previously, Camilla held roles as a Senior Research Scientist and Research Scientist in Pharmaceutical Development, focusing on formulation for injectable peptides and oral delivery of small molecules. Prior experience includes a position as a Formulation Engineer at Active Biotech AB, where pharmaceutical and analytical development was conducted, and as a Research Engineer at Ferring AB, focusing on peptide hormones for intranasal administration. Camilla holds a Master’s degree in Chemical Engineering from Lund University and has additional educational background from the Karlsruhe Institute of Technology.